MediWound Ltd. (NASDAQ:MDWD – Get Free Report) COO Shmuel Hess sold 1,865 shares of MediWound stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $13.00, for a total transaction of $24,245.00. The sale was disclosed in a filing with the SEC, which is accessible through this link.
Shmuel Hess also recently made the following trade(s):
- On Thursday, August 27th, Shmuel Hess sold 3,958 shares of MediWound stock. The shares were sold at an average price of $12.92, for a total transaction of $51,137.36.
MediWound Stock Down 4.4%
Shares of MDWD opened at $12.66 on Friday. The firm has a market capitalization of $162.68 million, a PE ratio of -7.03 and a beta of 0.15. The firm has a 50-day moving average price of $14.16 and a 200 day moving average price of $15.64. MediWound Ltd. has a 52-week low of $12.52 and a 52-week high of $20.30.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in MDWD. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of MediWound by 22.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock valued at $85,000 after acquiring an additional 999 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of MediWound by 4.4% in the 1st quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company’s stock worth $176,000 after acquiring an additional 481 shares during the last quarter. Russell Investments Group Ltd. raised its position in shares of MediWound by 69.1% during the second quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 649 shares during the period. Marshall Wace LLP purchased a new stake in shares of MediWound during the second quarter valued at $317,000. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of MediWound by 104.4% during the second quarter. The Manufacturers Life Insurance Company now owns 26,062 shares of the biopharmaceutical company’s stock valued at $505,000 after purchasing an additional 13,312 shares during the last quarter. Institutional investors and hedge funds own 46.83% of the company’s stock.
Wall Street Analyst Weigh In
A number of equities research analysts have weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of MediWound in a research report on Friday, July 17th. Wall Street Zen cut MediWound from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Oppenheimer reissued an “outperform” rating and issued a $30.00 price objective (down from $32.00) on shares of MediWound in a research note on Friday, August 14th. Finally, HC Wainwright restated a “buy” rating and issued a $36.00 price objective on shares of MediWound in a report on Thursday, May 28th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, MediWound presently has a consensus rating of “Hold” and a consensus price target of $33.00.
Get Our Latest Stock Analysis on MediWound
About MediWound
MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.
The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.
Featured Articles
- Five stocks we like better than MediWound
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
- These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.
